Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Particulate matters (PMs) increase oxidative stress and inflammatory response in different tissues. PMs disrupt the formation of primary cilia in various skin cells, including keratinocytes and melanocytes. In this study, we found that 2-isopropylmalic acid (2-IPMA) promoted primary ciliogenesis and restored the PM2.5-induced dysgenesis of primary cilia in dermal fibroblasts. Moreover, 2-IPMA inhibited the generation of excessive reactive oxygen species and the activation of stress kinase in PM2.5-treated dermal fibroblasts. Further, 2-IPMA inhibited the production of pro-inflammatory cytokines, including IL-6 and TNF-α, which were upregulated by PM2.5. However, the inhibition of primary ciliogenesis by IFT88 depletion reversed the downregulated cytokines by 2-IPMA. Moreover, we found that PM2.5 treatment increased the MMP-1 expression in dermal fibroblasts and a human 3-D-skin model. The reduced MMP-1 expression by 2-IPMA was further reversed by IFT88 depletion in PM2.5-treated dermal fibroblasts. These findings suggest that 2-IPMA ameliorates PM2.5-induced inflammation by promoting primary ciliogenesis in dermal fibroblasts.

Details

Title
Primary Ciliogenesis by 2-Isopropylmalic Acid Prevents PM2.5-Induced Inflammatory Response and MMP-1 Activation in Human Dermal Fibroblasts and a 3-D-Skin Model
Author
Bae, Ji-Eun 1 ; Daejin Min 2 ; Choi, Ji Yeon 3   VIAFID ORCID Logo  ; Choi, Hyunjung 2 ; Kim, Joon Bum 3 ; Park, Na Yeon 3 ; Doo, Sin Jo 3 ; Kim, Yong Hwan 3 ; Hye-Won Na 2 ; Kim, Yoon Jae 3 ; Eun Sung Kim 4 ; Kim, Hyoung-June 2 ; Dong-Hyung Cho 5 

 Brain Science and Engineering Institute, Kyungpook National University, Daegu 41566, Korea; [email protected] 
 R&D Center, AMOREPACIFIC Corporation, Yongin 17074, Korea; [email protected] (D.M.); [email protected] (H.C.); [email protected] (H.-W.N.) 
 School of Life Sciences, BK21 FOUR KNU Creative BioResearch Group, Kyungpook National University, Daegu 41566, Korea; [email protected] (J.Y.C.); [email protected] (J.B.K.); [email protected] (N.Y.P.); [email protected] (D.S.J.); [email protected] (Y.H.K.); [email protected] (Y.J.K.) 
 New Drug Development Center, Osong Medical Innovation Foundation, Cheongju 28160, Korea; [email protected] 
 Brain Science and Engineering Institute, Kyungpook National University, Daegu 41566, Korea; [email protected]; School of Life Sciences, BK21 FOUR KNU Creative BioResearch Group, Kyungpook National University, Daegu 41566, Korea; [email protected] (J.Y.C.); [email protected] (J.B.K.); [email protected] (N.Y.P.); [email protected] (D.S.J.); [email protected] (Y.H.K.); [email protected] (Y.J.K.) 
First page
10941
Publication year
2021
Publication date
2021
Publisher
MDPI AG
ISSN
16616596
e-ISSN
14220067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2584438474
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.